The seemingly sturdy U.S. stock market has begun to wobble. Its months-long tech-driven rally may be running out of steam ...

CoreWeave shares fell 16.3% after Q3 2025 earnings, primarily due to lowered full-year revenue guidance and concerns over its ...

The average one-year price target for NeoGenomics (NasdaqCM:NEO) has been revised to $12.44 / share. This is an increase of ...

In the current market session, Novo Nordisk Inc. (NYSE: NVO) price is at $48.56, after a 0.62% spike. However, over the past month, the stock fell by 11.35%, and in the past year, by 52.68%.

JKS reported mixed Q2 and Q3 2025 results, with improving profitability and rising momentum in energy-storage business.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Neo Performance Materials Inc ( ($TSE:NEO) ) has issued an announcement. Neo Performance Materials Inc. reported strong third-quarter financial ...